Equities research analysts expect that Regulus Therapeutics Inc (NASDAQ:RGLS) will announce earnings of ($0.07) per share for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Regulus Therapeutics’ earnings, with the highest EPS estimate coming in at $0.11 and the lowest estimate coming in at ($0.24). Regulus Therapeutics posted earnings per share of ($0.98) during the same quarter last year, which suggests a positive year-over-year growth rate of 92.9%. The business is expected to announce its next quarterly earnings results on Monday, March 16th.
According to Zacks, analysts expect that Regulus Therapeutics will report full-year earnings of ($0.86) per share for the current year, with EPS estimates ranging from ($1.12) to ($0.59). For the next year, analysts forecast that the company will report earnings of ($0.87) per share, with EPS estimates ranging from ($1.03) to ($0.70). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that cover Regulus Therapeutics.
Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.26). Regulus Therapeutics had a negative return on equity of 163,378.48% and a negative net margin of 325.85%. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.02 million.
Shares of NASDAQ RGLS traded down $0.04 during midday trading on Tuesday, hitting $0.74. The stock had a trading volume of 26,583 shares, compared to its average volume of 182,084. The company has a market capitalization of $15.50 million, a price-to-earnings ratio of -0.13 and a beta of 1.55. Regulus Therapeutics has a 1-year low of $0.50 and a 1-year high of $1.65. The company has a fifty day moving average price of $0.71 and a 200 day moving average price of $0.84.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. CVI Holdings LLC acquired a new position in shares of Regulus Therapeutics in the 2nd quarter valued at about $568,000. Samsara BioCapital LLC acquired a new position in shares of Regulus Therapeutics in the 2nd quarter valued at about $1,131,000. EcoR1 Capital LLC acquired a new position in shares of Regulus Therapeutics in the 2nd quarter valued at about $1,389,000. Finally, NEA Management Company LLC lifted its stake in shares of Regulus Therapeutics by 124.1% in the 2nd quarter. NEA Management Company LLC now owns 2,052,455 shares of the biopharmaceutical company’s stock valued at $2,566,000 after purchasing an additional 1,136,704 shares in the last quarter. 36.84% of the stock is currently owned by institutional investors and hedge funds.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
See Also: Buy-Side Analysts
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.